Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bbbiotech.com, you confirm that you have read, understood and accepted the general information provided by the BB Biotech AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions. Alternatively, you can select "I don't accept" if you wish to leave the website.

Investment Themes

The dynamics of the biotech sector are enormous. Numerous trends are emerging, which the investment management team is scrutinizing and taking into account in the investment strategy. We present a selection of exciting fields.
  • Gene therapies

    Gene therapies aim to provide a permanent cure rather than just managing a disease. Specifically, the goal is to fix an inherited genetic defect. The trigger of disease is an error in the genetic information that may for instance cause a certain protein to be non-functioning. Treatments such as enzyme replacement therapy remedy this deficiency. Certain virus types such as adeno-associated viruses or retroviruses act as messengers by inserting the desired gene into the cell so that the information is read and implemented.

  • Neurological Diseases

    open glightbox

    Neurological Diseases

    Neurological diseases span a broad spectrum of brain and peripheral nervous system dysfunction, including conditions such as Alzheimer’s, Parkinson’s, depression, migraine and multiple sclerosis. Rapid aging of the global population poses growing challenges to healthcare systems. On top of the increasing cost of medicines, the cost of residential care adds to the burden. The demand for new therapies that modify disease outcome instead of just relieving symptoms is all the more urgent.

  • Artificial intelligence 

    open glightbox

    Artificial intelligence 

    Artificial intelligence can be used, for example, to identify the most suitable development candidates more quickly and at less cost. Collaborative interaction between humans and machines is vital here, and a balance must be found between in silico experimentation and in vitro experiments. The objective is to support the efforts of scientists through the use of AI.

  • RNA therapies 

    RNA-based therapeutics act like a kind of biological software that uses a genetic search-and-delete mechanism to block the production of disease-causing proteins. The drugs do this by targeting RNA, the substance that carries the instructions for making and assembling proteins inside our cells.